The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR from the National Institute of Drug Abuse Entitled "Trigriluzole for the Treatment of Cocaine Abuse"

 

Doylestown, PA. June 6, 2018 - FCCDC is pleased to report that it has received a Phase I STTR from the National Institute of Drug Abuse (R41DA047169-01) entitled "Trigriluzole for the Treatment of Cocaine Abuse", Prof. Scott Rawls, Temple University, Principal Investigator."